5-Amino-1-MQ: NNMT Inhibitor and Metabolic Pathway Guide

By Sam Smith

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme researchers have identified as a key regulator of adipose tissue energy expenditure and metabolic health. In diet-induced obese mouse models, 5-Amino-1MQ treatment reduces body weight, shrinks fat cell size, and improves insulin sensitivity by conserving SAM and NAD+ precursor pools inside adipocytes. This is not a peptide; its mechanism operates upstream of the receptor-level signalling that defines GLP-1 agonists and growth hormone secretagogues.

This guide covers what 5-Amino-1MQ does in metabolic research, how NNMT inhibition reshapes adipocyte energy metabolism, what rodent obesity studies show on body composition outcomes, how the compound compares to peptide-based interventions, and sourcing considerations for research use. All primary claims are linked to peer-reviewed sources.

What is 5-Amino-1MQ used for?

5-Amino-1MQ is a chemical probe for studying the NNMT pathway in metabolic disease. Researchers use it in rodent obesity models, hepatic steatosis experiments, adipose tissue energy expenditure studies, and aging-related metabolic decline work. It is sold for research use only and carries no approval from Health Canada or the FDA for any therapeutic indication. Think of it less as a drug candidate and more as a molecular tool — one that lets investigators isolate the specific contribution of NNMT activity to metabolic dysfunction in a living system.

What is NNMT and why does inhibiting it matter?

NNMT (nicotinamide N-methyltransferase) transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. In white adipose tissue and liver, this reaction drains both SAM and NAD+ precursor pools — acting as what metabolic researchers describe as a “futile cycle” that diverts methyl groups away from productive cellular reactions. Kraus et al. (2014, Nature Medicine) showed NNMT expression is elevated in WAT and liver of obese and diabetic mice, positioning the enzyme as a driver of metabolic dysfunction rather than a bystander effect.

Inhibiting NNMT reverses the drain: SAM accumulates for productive methylation reactions, and nicotinamide flows into NAD+ biosynthesis rather than being lost to 1-methylnicotinamide. That shift, according to a 2021 NNMT knockdown study in obese mice, significantly increases whole-body energy expenditure, reduces body weight, and restores insulin sensitivity — all without direct receptor agonism.

Mechanism of action of 5-Amino-1MQ

5-Amino-1MQ is a methylquinolinium-scaffold NNMT inhibitor with a primary amine substituent that increases cell membrane permeability. Neelakantan et al. (2019, Journal of Medicinal Chemistry) identified 5-amino-1MQ as the lead compound from a series of methylquinolinium analogues based on its combination of NNMT potency, membrane permeability, and selectivity relative to other methyltransferases. It binds competitively to the nicotinamide-binding pocket of NNMT, blocking substrate access without covalent modification of the enzyme.

Downstream of NNMT inhibition, adipocytes accumulate SAM, reduce S-adenosylhomocysteine, and channel more nicotinamide into NAD+ regeneration. Those shifts trigger higher mitochondrial biogenesis marker expression, elevated thermogenic gene activity (including UCP1 in beige adipose depots), and measurably increased cellular energy expenditure. At the whole-animal level, this shows up as smaller adipocytes on histology, lower fat mass, and improved glucose homeostasis.

Body composition and fat loss data

The most replicated fat loss signal comes from diet-induced obese (DIO) mouse models. A 2024 study reported that 5-Amino-1MQ dose-dependently reduced body weight gain and fat mass accumulation in DIO mice versus vehicle controls. A 2022 metabolic study documented dramatic whole-body adiposity reduction and weight loss in DIO mice treated over standard preclinical windows of 4 to 8 weeks.

A key data point worth flagging for researchers: in the Neelakantan et al. (2019) medicinal chemistry work, the lead 5-Amino-1MQ compound produced a statistically significant reduction in adipocyte size at 10 mg/kg/day in obese mice, alongside a 7–9% decrease in total body fat percentage — without muscle mass loss on tissue analysis. That fat-specific selectivity is one reason NNMT inhibition is considered mechanistically distinct from non-selective caloric restriction models.

Secondary metabolic improvements are consistent across published studies: reduced hepatic triglyceride content, lower fasting insulin, improved HOMA-IR scores, and elevated brown adipose tissue thermogenic marker expression. The mechanism — SAM and NAD+ conservation — is coherent across all of these endpoints.

How long does it take to see results?

In rodent studies, body weight curves diverge from vehicle controls within 2 to 4 weeks at standard preclinical doses. Fat mass differences reach statistical significance by week 6 to 8 in most published protocols. Insulin sensitivity improvements appear in the same timeframe. There is no validated human-translation timeline. No completed human clinical trial of 5-Amino-1MQ for obesity or body composition has been published as of 2026.

5-Amino-1MQ vs peptide weight-loss interventions

5-Amino-1MQ is not a peptide and does not compete with peptide-based metabolic interventions on mechanism. GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) suppress appetite and slow gastric emptying through incretin receptors. AOD-9604 targets beta-3 adrenergic receptors as a lipolytic fragment. Tesamorelin drives visceral fat reduction through GHRH signalling. 5-Amino-1MQ acts intracellularly on the methyl-group economy of adipocytes. Because these pharmacology classes target independent pathways, researchers sometimes combine them to interrogate additive or synergistic effects — that is the scientific rationale for multi-compound study designs, not therapeutic recommendation.

Dosing and routes of administration in research

Published rodent studies administer 5-Amino-1MQ by intraperitoneal injection or oral gavage at 10 to 50 mg/kg/day. The compound is orally bioavailable — a practical advantage over peptide-based interventions that require injection. Standard preclinical dosing windows run 4 to 12 weeks. No human pharmacokinetic data has been published, and no validated human dose-conversion exists from the rodent literature.

Side effects and safety in preclinical data

Published rodent toxicology at standard preclinical doses has not identified hepatotoxicity, cardiac effects, or renal toxicity. Body composition shifts toward leaner phenotypes without reported muscle wasting. The primary theoretical concern is off-target methyltransferase inhibition — any small molecule binding the nicotinamide site of one methyltransferase carries some risk of affecting others. Published selectivity profiles for 5-Amino-1MQ show acceptable specificity versus related enzymes, though long-term toxicology studies have not been completed. Human safety data is entirely absent.

Legal status

5-Amino-1MQ is legal in Canada and the United States as a research chemical sold under research-use-only labelling. Health Canada and the FDA have not approved it for any therapeutic indication. It does not appear on the World Anti-Doping Agency prohibited list as of 2026, though athletes operating under WADA jurisdiction should monitor regulatory updates independently.

Available forms and sourcing

5-Amino-1MQ is supplied as powder or oral capsule for research use. Purity specifications to request: HPLC ≥98%, mass spectrometry identity confirmation against the expected molecular weight of 175.21 g/mol. Because it is a small molecule rather than a peptide, it is more storage-stable under standard conditions — no cold-chain shipping required for short-term transport.

Reviv Peptides supplies 5-Amino-1MQ in research-grade format with COA and HPLC purity confirmation. View the 5-Amino-1MQ product page.

5-Amino-1MQ questions

What is 5-Amino-1MQ used for?

5-Amino-1MQ is used in research as a chemical probe for the NNMT pathway in obesity, fat loss, hepatic steatosis, and aging biology. It is not approved for any human therapeutic indication and is sold for research use only.

What is the mechanism of action of 5-Amino-1MQ?

5-Amino-1MQ competitively inhibits nicotinamide N-methyltransferase (NNMT) at the nicotinamide-binding pocket. This preserves SAM and NAD+ precursor availability in adipocytes, increasing thermogenic gene expression, mitochondrial biogenesis markers, and cellular energy expenditure — resulting in reduced fat mass and improved insulin sensitivity in rodent obesity models.

What are the side effects and safety considerations of 5-Amino-1MQ?

Preclinical rodent data shows no hepatotoxicity or cardiac effects at standard doses. Off-target methyltransferase inhibition is the main theoretical risk. Published selectivity profiles are acceptable. Long-term toxicology is incomplete, and human safety data is absent.

How long does it take to see results from 5-Amino-1MQ?

In rodent studies, body weight diverges from vehicle controls within 2 to 4 weeks; fat mass differences become statistically significant by 6 to 8 weeks. No human-translation timeline exists — no completed human trial has been published.

What is the legal status of 5-Amino-1MQ?

5-Amino-1MQ is legal in Canada and the United States as a research chemical under research-use-only labelling. It is not approved for any therapeutic indication and does not appear on the WADA prohibited list as of 2026.

Summary

5-Amino-1MQ is the best-validated small-molecule probe for the NNMT pathway in obesity and metabolic research. It reduces body weight, fat mass, and adipocyte size in DIO mouse models; improves insulin sensitivity; and elevates cellular energy expenditure — all through intracellular methyl-group economy rather than receptor signalling. It is not a peptide, not approved for human use, and has no completed human trial data. For researchers studying metabolic dysfunction through the NNMT axis, it is the reference compound in the scaffold class.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.